Personalized Medicine for Breast Cancer: Update and New Challenge
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 66
Special Issue Editors
2. James Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Interests: breast cancer; breast biomarkers; precision oncology; tumor microenvironment; immunotherapy
2. James Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA
Interests: breast cancer; liquid biopsies; genomic profiling; personalized medicine
Special Issue Information
Dear Colleagues,
The era of personalized medicine has ushered in a paradigm shift in breast cancer management, enabling treatment strategies informed by tumor genomics, transcriptomic profiling, and host-specific factors. Advances in next-generation sequencing, liquid biopsy technologies, and multi-omics integration have facilitated the identification of actionable alterations, leading to the development and regulatory approval of biomarker-driven therapies. Precision approaches—such as HER2-targeted therapies, CDK4/6 inhibitors, PI3K inhibitors, PARP inhibitors, and antibody–drug conjugates—have significantly improved clinical outcomes across multiple breast cancer subtypes.
Despite these advances, significant challenges persist. Access to genomic testing and targeted therapies is not uniform across populations, contributing to disparities in care. Biomarker discovery and validation—particularly in subtypes such as triple-negative and HER2-low breast cancer—remain areas of active investigation. The optimal sequencing of therapies, strategies to overcome primary and acquired resistance, and the incorporation of real-world evidence into clinical decision-making are also ongoing challenges. Furthermore, the integration of precision diagnostics into routine practice and ensuring equitable access to personalized treatment options are critical goals yet to be fully realized.
This Special Issue seeks to highlight recent advances and emerging challenges in the field of personalized medicine for breast cancer. We invite original research articles, reviews, and expert perspectives focusing on novel biomarkers, resistance mechanisms, therapeutic sequencing, disparities in precision care, translational strategies, and innovations in diagnostics and clinical trial design. Our aim is to foster cross-disciplinary dialogue and accelerate progress toward equitable, individualized breast cancer care.
Dr. Arya Mariam Roy
Dr. Daniel Stover
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- personalized Medicine
- tumor genomics
- biomarker discovery
- targeted therapy therapy resistance antibody-drug conjugates
- genomic profiling
- liquid biopsy
- therapeutic sequencing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
